Diabetes is a metabolic disorder that develops when the body is unable to produce or effectively use insulin the hormone ...

The survey highlights a preference for collaborative learning methods, with 75% of respondents favoring clinical case ...

Several districts across Nagaland observed World Diabetes Day on Thursday on the theme “Breaking barriers, bridging gaps.” ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Weight gain, particularly abdominal obesity, significantly impacts individuals with metabolic syndrome. It exacerbates ...

The long-term consequences of this metabolic dysfunction are extensive. (Image Credits: Pixabay) Diabetes risk and obesity: ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase ...